1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cardiac Safety Services Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of cardiovascular disorders and the need for effective & safe treatment
5.1.1.2. Use of biosimilars and biomarkers to detect cardiotoxicity or cardiovascular risks
5.1.1.3. Government initiatives encouraging personalized treatments in cardiology
5.1.2. Restraints
5.1.2.1. Relatively high cost of cardiac evaluation services and limited availability of skilled professionals
5.1.3. Opportunities
5.1.3.1. Advancements in cardiac safety testing and monitoring systems
5.1.3.2. Growing number of clinical trials and R&D for cardiac treatments
5.1.4. Challenges
5.1.4.1. Lack of regulatory standardization across various countries
5.2. Market Segmentation Analysis
5.2.1. Service Type: Proliferating need for efficient cardiovascular imaging services
5.2.2. Type: Expanding use of integrated cardiac safety services for drug development
5.2.3. End-User: Surging adoption of cardiac safety services by pharmaceutical & biopharmaceutical companies
5.3. Market Trend Analysis
5.3.1. Highly advanced healthcare infrastructure and presence of established vendors favored by supportive regulatory landscape in the Americas
5.3.2. Potential of the Asia-Pacific to be a preferred arena for cardiology trials and expanding adoption cardiovascular disease treatment
5.3.3. Well-defined regulatory standards surrounding cardiac safety in Europe and the rise of the Middle East & Africa as a potential clinical trial hub
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization
6. Cardiac Safety Services Market, by Service Type
6.1. Introduction
6.2. Blood Pressure Measurement Services
6.3. Cardiovascular Imaging Services
6.4. ECG or Holter Measurement Services
6.5. Thorough QT Studies
7. Cardiac Safety Services Market, by Type
7.1. Introduction
7.2. Integrated Services
7.3. Standalone Services
8. Cardiac Safety Services Market, by End-User
8.1. Introduction
8.2. Contract Research Organizations
8.3. Pharmaceutical & Biopharmaceutical Companies
9. Americas Cardiac Safety Services Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cardiac Safety Services Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cardiac Safety Services Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Merger & Acquisition
12.3.1.1. Abbott Completes USD 890 Million Acquisition of Cardiovascular Systems
12.3.2. Agreement, Collaboration, & Partnership
12.3.2.1. Jubilant Radiopharma and Cardiac Imaging, Inc. Announce Exclusive Partnership to Expand Access for Mobile Cardiac PET Offering
12.3.2.2. Clario and AliveCor Collaborate to Offer Advanced, Trial-Focused Six-Lead ECG Solutions for Monitoring in Decentralized Clinical Trials
12.3.2.3. AliveCor, Luscii Partner On ‘Heart Clinic In a Box’
12.3.2.4. Philips, Biotronik Partner to Expand Care for Out-of-Hospital Cardiology Labs
12.3.2.5. Philips and TriHealth Announce Multi-Year Partnership at Heart of New Trihealth Heart & Vascular Institute on the Campus of Bethesda North Hospital
12.3.3. New Product Launch & Enhancement
12.3.3.1. GE HealthCare Announces Vscan Air SL Device for Cardiac, Vascular Patients
12.3.3.2. Metrion Biosciences Announces Launch of Good Laboratory Practice (GLP) hERG Screening Service
12.3.3.3. Heartnet Launches Telecardiology Product ASAAN
12.3.4. Award, Recognition, & Expansion
12.3.4.1. OSF HealthCare Establishes a Partnership with Bellin Health to Expand Cardiovascular Services in Delta County
12.3.4.2. Abbott Receives FDA Approval for World’s First Dual Chamber Leadless Pacemaker
12.3.4.3. Banook Group Continues Global Expansion with the U.S. Office Opening
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AliveCor, Inc.
13.1.3. Banook Group
13.1.4. Biotrial
13.1.5. Butterfly Network Inc.
13.1.6. Celerion
13.1.7. Certara, Inc.
13.1.8. Circle Cardiovascular Imaging Inc.
13.1.9. Clario
13.1.10. Clyde Biosciences Limited
13.1.11. Dozee
13.1.12. Eurofins Scientific SE
13.1.13. GE HealthCare Technologies Inc.
13.1.14. ICON PLC
13.1.15. IQVIA Holdings Inc.
13.1.16. Koninklijke Philips N.V.
13.1.17. Laboratory Corporation of America Holdings
13.1.18. Lunit Inc.
13.1.19. Medpace, Inc.
13.1.20. MERIT CRO, Inc.
13.1.21. Metrion Biosciences Limited
13.1.22. Ncardia Services B.V.
13.1.23. NEXEL Co., Ltd.
13.1.24. Octagos Health, Inc.
13.1.25. PhysioStim SAS
13.1.26. Richmond Pharmacology Limited
13.1.27. Shanghai Medicilon Inc.
13.1.28. Siemens Healthcare GmbH
13.1.29. Tempus Labs, Inc.
13.1.30. Thermo Fisher Scientific Inc.
13.1.31. Toray Medical Company Limited by Toray Industries
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
